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Abstract 
Background: Malaria remains a public health challenge in sub-Saharan Africa with Plasmodium falciparum being the 
principal cause of malaria disease morbidity and mortality. Plasmodium falciparum virulence is attributed, in part, to its 
population-level genetic diversity—a characteristic that has yet to be studied in Rwanda. Characterizing P. falciparum 
molecular epidemiology in an area is needed for a better understand of malaria transmission and to inform choice of 
malaria control strategies.
Methods: In this health-facility based survey, malaria case clinical profiles and parasite densities as well as parasite 
genetic diversity were compared among P. falciparum-infected patients identified at two sites of different malaria 
transmission intensities in Rwanda. Data on demographics and clinical features and finger-prick blood samples for 
microscopy and parasite genotyping were collected. Nested PCR was used to genotype msp-2 alleles of FC27 and 
3D7.
Results: Patients’ variables of age group, sex, fever (both by patient report and by measured tympanic temperatures), 
parasite density, and bed net use were found differentially distributed between the higher endemic (Ruhuha) and 
lower endemic (Mubuga) sites. Overall multiplicity of P. falciparum infection (MOI) was 1.73 but with mean MOI found 
to vary significantly between 2.13 at Ruhuha and 1.29 at Mubuga (p < 0.0001). At Ruhuha, expected heterozygosity 
(EH) for FC27 and 3D7 alleles were 0.62 and 0.49, respectively, whilst at Mubuga, EH for FC27 and 3D7 were 0.26 and 
0.28, respectively.
Conclusions: In this study, a higher geometrical mean parasite counts, more polyclonal infections, higher MOI, and 
higher allelic frequency were observed at the higher malaria-endemic (Ruhuha) compared to the lower malaria-
endemic (Mubuga) area. These differences in malaria risk and MOI should be considered when choosing setting-spe-
cific malaria control strategies, assessing p. falciparum associated parameters such as drug resistance, immunity and 
impact of used interventions, and in proper interpretation of malaria vaccine studies.
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Background
In spite of the significant decline in malaria cases and 
deaths being reported globally, malaria still accounted 
for about 200 million cases and over 500,000 deaths in 
2014 [1]. The malaria burden decline, particularly in 
sub-Saharan Africa, has been associated with the rapid 
scaling-up of interventions including long-lasting insecti-
cide-treated nets (LLINs), indoor residual spraying (IRS) 
with insecticides, and use of artemisinin-based combi-
national therapy (ACT) for managing uncomplicated 
malaria cases [2]. Scale-up of LLINs, IRS and ACT imple-
mentation in Rwanda was associated with a more than 
50 % decline in malaria morbidity and mortality among 
children aged under 5 years between 2005 and 2010 [3]. 
In spite of these declines however, malaria is still a pub-
lic health challenge with the entire Rwandese population 
considered as being at risk.
Human malaria infections exhibit a broad clinical spec-
trum ranging from asymptomatic infection to severe 
life-threatening disease. Disease severity is influenced 
by interactions between parasite, human host and envi-
ronmental factors, including, but not limited to, anti-
malaria therapies used, levels of immunity, age, sex, and 
pregnancy status [4]. With regard to anti-malaria thera-
pies in Rwanda, resistance in Plasmodium falciparum in 
the past led to chloroquine being replaced with amodi-
aquine (AQ) + sulfadoxine–pyrimethamine (SP) in 2001 
and then later, AQ + SP combination was subsequently 
replaced with artemether–lumefantrine (AL) in 2006, 
as first-line anti-malarial therapies for uncomplicated 
malaria. Malaria transmission levels and the associated 
risk of morbidity and mortality show a spatial heteroge-
neity even within small countries such as Rwanda [5, 6]. 
Current Rwandan malaria heterogeneity is partly influ-
enced by the variations in type and intensity of malaria 
control interventions deployed across different settings 
as well as the baseline residual transmission potentials at 
the four different malaria transmission zones [5]. Under-
standing malaria disease severity, including clinical fea-
tures and parasitaemia levels associated with malaria 
disease, in populations from areas of differing malaria 
transmission intensities is needed for decision making on 
which control tools may have optimal impact.
Plasmodium falciparum is the most prevalent cause 
of malaria morbidity and mortality in Rwanda [5]. Plas-
modium falciparum virulence is mediated, in part, by 
its population-level genetic diversity which has been 
reported to influence malaria disease pathology [7–9], 
acquisition of immunity [10, 11], infection transmission 
intensity [12–14], and vaccine responses [15, 16]. High 
malaria-endemic areas tend to have extensive P. falcipa-
rum genetic diversity with infected humans often found 
with multiple genotypes. Conversely, low transmission 
areas tend to yield limited P. falciparum genetic diversity 
with a higher proportion of infections being monoclonal 
[17–20].
Studying plasmodial molecular epidemiology is essen-
tial to understanding malaria transmission. Currently, 
malaria disease severity among health facility-identi-
fied cases as well as population-level parasite diversity 
remains unknown in Rwanda. This study compared clini-
cal profiles of malaria-confirmed cases, parasite densities 
and P. falciparum genetic diversity [21, 22] based on the 
msp-2 gene—a valid, reliable and highly discriminatory 
and polymorphic marker used for genetic finger printing, 




Rwanda is divided into four malaria ecologic zones based 
on altitude, climate, level of transmission, and disease 
vector prevalence [5]. Malaria cases for this cross-sec-
tional survey were recruited from rural Ruhuha sector 
(Bugesera District, Eastern Province) and Mubuga sec-
tor (Karongi District, Western Province) (Fig. 1) located 
in the highest and lowest malaria transmission zones, 
respectively [5].
Baseline demographics, clinical features and blood sample 
collection
All health facility-visiting cases aged ≥6  months who 
were microscopically confirmed by the health facility 
laboratory technicians to be P. falciparum infected in 
the period 15th January to 15th February 2015 were eli-
gible for enrolment. Upon provision of written informed 
consent, a brief structured questionnaire was adminis-
tered to collect data on demographics (sex, age, area of 
residence), fever history, and bed net use on the night 
before the survey. In addition, body temperature was 
measured using an electronic tympanic thermometer 
and a second round of finger-prick blood samples taken 
off to prepare thick and thin smears for analysis by the 
study laboratory technicians and for blotting on to filter 
papers (Whatman 3MM) for use in performing molecu-
lar studies.
Preparation of blood films, microscopic examination 
and quality assurance
Thick blood smears were stained with 3  % Giemsa for 
60  min and slides read by two blinded study microsco-
pists. In case of two discordant results, a third reader was 
used to resolve the discrepancy. Using the thick blood 
smear, parasite densities were enumerated as the number 
of counts of asexual parasites per 200 leukocytes, assum-
ing a median leukocyte count of 8000/μL. Thin smears 
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were used to differentiate Plasmodium species. External 
quality control was done on a 10 % sample of randomly 
selected thick and thin smears by microscopists at the 
National Reference Laboratory, Kigali, Rwanda whose 
results were in agreement with those reported by the 
study technicians.
Plasmodium falciparum DNA extraction and msp‑2 allelic 
typing
DNA was extracted with Chelex 100 Resin (Bio-Rad Lab-
oratories, Hercules, CA, USA) as previously described 
[23]. The surface antigen loci msp-2 was amplified using 
previously described primers [24]. Briefly, 2  μL of tem-
plate DNA was amplified using nested polymerase chain 
reaction (nPCR), with second-round primers specific to 
msp-2 allelic families. PCR products were then separated 
on a 2.5  % agarose gel (UltraPure Agarose; Invitrogen, 
Carlsbad, CA, USA) and stained with ethidium bromide. 
GelCompar II software (Applied Maths, Sint-Martens-
Latem, Belgium) was used to select alleles and estimate 
PCR product size as described elsewhere [21].
Statistical analysis
Demographics, clinical features and bed net use data 
were collected using hard copy study case record forms 
while laboratory results were transcribed into study labo-
ratory registers. Both datasets were double-entered into 
EPI Info™ 7 (Centres for Disease Control and Prevention, 
GA, USA) database and later transferred into STATA 
(version 13.1, College Station, TX, USA) for analysis. Par-
asitaemia—the number of parasites/μL was graded as low 
(<1000), moderate (1000–9999) and high (>10,000) as 
per WHO parasitaemia cut-off for severe malaria in low 
transmission settings [25]. MOI was defined as the pro-
portion of people who carry more than one allele (geno-
type) for any of the examined genes. Mean multiplicity of 
infection (MOI) was estimated by dividing the total num-
ber of distinct msp2 genotypes detected by the number of 
positive samples.
Descriptive statistics of proportions and means were 
used to summarize distributions of allelic families, baseline 
demographics, MOI, and other covariate data. Chi square 
tests were used to compare mean MOI and allelic variant 
Fig. 1 Location map showing study sites of Ruhuha# and Mubuga# sectors in Rwanda. #Ruhuha sector is located in Bugesera District, Eastern 
Rwanda whilst Mubuga sectors is located in Karongi District, Western Rwanda
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distributions between study sites. Independent t test was 
used to compare mean MOI outcome by independent fac-
tors of age group, study site, history of fever and presence of 
measured fever (≥37.5 °C), sex and bed net use. Expected 
heterozygosity index (HE)—which measures locus diver-
sity—was calculated using the formulae HE  =  [n/(n–1)] 
[(1–!Pi2)], where n  =  sample size, Pi  =  allelic frequency. 
Odds ratios (ORs) and 95 % confidence intervals (CIs) were 
calculated to evaluate the strengths of associations. Statisti-
cal significance was defined as p value ≤ 0.05 [22].
Ethical clearance
All adults and carers of children <18  years old were 
informed of the purpose and procedures of the study, and 
recruited only after obtaining informed written consent. 
The study was approved by the National Health Research 
Committee and the Rwanda National Ethics Committee 
(No. 20/RNEC/2015), Kigali, Rwanda.
Results
Baseline study participant demographics
A total of 407 patients who were microscopically con-
firmed with malaria by health facility laboratory tech-
nicians were enrolled. Of these, 402 (98.8  %) were 
microscopically re-confirmed by study-trained techni-
cians to be malaria positive. Of the 402, final data analy-
sis was performed on 388 (96.5 %) who were successfully 
genotyped for the msp-2 alleles. Stratified by site, 195 
(50.3 %) cases were enrolled at Ruhuha whilst 193 (49.7 %) 
enrolled at Mubuga (Table  1). A higher proportion 
(55.4  %) of study participants were females. The overall 
group mean age was 15.5 years (SD ± 13.6). Overall geo-
metric mean parasite density was 1119.3 parasites/μL.
Demographics, clinical features, parasitological 
and malaria control use distributions among participants 
from the two study sites
The results of group comparisons of demographic, bed 
net use, fever experiences, and parasite density among 
patients from the two study sites are shown in Table  1. 
Significant differences in proportions of participant char-
acteristics of sex (p = 0.04) and age group (p = <0.0001) 
between patients from Ruhuha and Mubuga sites were 
noted. At Ruhuha, a higher proportion (60.5  %) of 
patients were females compared to Mubuga (50.3  %). 
Among children aged <5 years, a higher proportion was 
seen at Ruhuha (26.7  %) compared to Mubuga (11.4  %) 
while among those aged >15  years, a higher proportion 
was enrolled at Mubuga (40.4  %) compared to Ruhuha 
(24.6 %). With regard to history of reported fever, a sig-
nificantly (p = 0.001) higher proportion (99 %) was noted 
at Ruhuha compared to that reported at Mubuga (84 %). 
In contrast, a significantly higher proportion of patients 
(p  =  0.001) with a measured temperature of ≥37.5  °C 
were seen at Mubuga (58.5 %) compared to that reported 
from Ruhuha (41.5 %). A significantly higher proportion 
(38.0  %) of patients at Ruhuha had high parasite count 
(>10,000 parasites/μL) than those seen at Mubuga (3.1 %; 
Table 1 Demographics, malaria prevention, clinical profiles and geometric mean parasite densities/*μL for malaria cases 
identified in Ruhuha and Mubuga sites in Rwanda
χ2 chi square test
Variables Ruhuha site n = 195 Mubuga site n = 193 Pearson’s χ2 test
Demographics Variable sub‑groups n (%) n (%)
Age groups 6 months–5 years 52 (26.7) 22 (11.4) –
6–15 years 95 (48.7) 93 (48.2) –
16–73 years 48 (24.6) 78 (40.4) <0.0001
Sex Males 77 (39.5) 96 (49.7) –
Females 118 (60.5) 97 (50.3) 0.042
Malaria prevention used Number reporting bed net use  
night prior to survey
129 (66.2) 150 (77.7) 0.011
Fever history and experience Number with history of fever in  
previous 24 h
192 (98.5) 162 (83.9) <0.0001
Number with tympanic temperature  
of ≥37.5 °C
78 (41.5) 110 (58.5) 0.001
Parasitology Parasite count ranges/per μL Low 
(<1000)
63 (32.3) 113 (58.6)
Moderate (1000–9999) 58 (29.7) 74 (38.3)
Severe (≥10,000) 74 (38.0) 6 (3.1) <0.0001
Geometric mean parasitaemia  
(parasites/μL)
2347.3 (95 % CI: 1772.1–3109.2) 529.7 (95 % CI: 402.3–697.4) <0.0001
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p  <  0.0001). Similarly, geometric mean parasitaemia 
counts were higher at Ruhuha (95 % CI: 5686.5–7394.8) 
than at Mubuga (95  % CI: 1383.3–2251.7). Bed net use 
was significantly higher at Mubuga (77.7  %) than at 
Ruhuha (66.2 %) (p = 0.001).
Infection clones and allelic diversity
Overall, a range of one to six infection clones per sam-
ple was seen. At both sites, about 55.4 % of the infections 
were monoclonal, with isolates from the Mubuga site 
carrying a significantly higher proportion of monoclonal 
infections (73 %) compared to those from Ruhuha (38 %) 
(p < 0.0001). The numbers of strains per isolate are pre-
sented in Table 2. Overall, a total of 80 (27.8 %) samples 
were co-infected by both FC27 and 3D7 types but with 
the number of strains per isolate noted to be higher at 
Ruhuha (p < 0.0001) compared to Mubuga (Table 2). In 
total, more 3D7 allelic variants were detected (298) com-
pared to FC27 variant (184) alleles.
Allelic frequency and heterozygosity
For both FC27 and 3D7 alleles, 760 distinct P. falcipa-
rum clones were detected (Table 2). Parasite allelic fre-
quency varied among isolates from the two study sites 
(Figs.  2, 3). Overall, the majority (68  %) of isolates car-
ried the FC27 300–330-bp size fragment (Fig.  3) while 
70 % carried the 3D7 200–300-bp size fragment (Fig. 2). 
At Ruhuha, HE for 3D7 and FC27 was 0.49 and 0.62 
while at Mubuga, HE for 3D7 and FC27 was 0.28 and 
0.26, respectively (Table  2). At each of the 3D7 (Fig.  2) 
and FC27 (Fig. 3) alleles, higher levels of polymorphisms 
were seen among isolates from Ruhuha than isolates 
from Mubuga.
Multiplicity of infection
Results for determinants of MOI are shown in Table  3. 
Overall, MOI for all infections at both sites was ~1.7. 
However, MOI varied significantly (p < 0.0001) between 
Mubuga (1.3) and Ruhuha (2.1). In this study, MOI was 
seen to increase proportional to age group being from 1.7 
among those under 5 years old to 1.9 among those aged 
6–15 years and 1.5 among those >15 years. Isolates from 
Ruhuha also had higher MOI compared to those from 
Mubuga.
Discussion
This study reports, for the first time in Rwanda, a dif-
ferential spatial distribution of patient demographics 
of age and sex, fever, parasite density and P. falciparum 
genetic diversity across two study sites. A higher geo-
metrical mean parasite counts (2347 vs 530 parasites), 
more polyclonal infections, higher MOI and higher allelic 
frequency were observed at higher malaria-endemic 
Ruhuha compared to the lower malaria-endemic Mubuga 
area.
A higher proportion of children aged <5  years was 
enrolled at Ruhuha compared to Mubuga while, in con-
trast, a higher proportion of those aged >15  years was 
recruited at Mubuga compared to Ruhuha. Higher 
malaria burden in younger age groups in settings of high 
malaria transmission intensity have been reported pre-
viously [26–28]. The age-related association of disease 
severity across different malaria transmission zones is 
currently poorly elucidated particularly in the era of 
scaled-up interventions such as LLINs and IRS whose 
impact on reducing malaria transmission has also influ-
enced age-related malaria risk. As reported elsewhere 
Table 2 Plasmodium falciparum msp-2 PCR product num-
bers, size by base pair range and HE for isolates with ≥one 
allele identified
a 3D7 strain difference in distribution = χ2 < 0.0001





Ruhuha n (%) Mubuga n (%)
Number of clones 
per sample
1 74 (38.0) 141 (73.0)
2 60 (30.8) 48 (24.9)
3 35 (17.9) 3 (1.6)
4 18 (9.2) 1 (0.5)
5 3 (1.5) 0 (0.0)
6 5 (2.6) 0
msp-2 strain distribution
3D7 straina 0 33 (16.9) 65 (33.7)
1 93 (47.7) 122 (63.2)
2 53 (27.2) 5 (2.6)
3 15 (7.7) 1 (0.3)
4 1 (0.5) 0 (0.0)
FC27 strainb 0 78 (40.0) 86 (44.6)
1 86 (44.1) 99 (51.3)
2 15 (7.7) 8 (4.2)
3 11 (5.6) 0 (0.0)
4 5 (2.6) 0 (0.0)
PCR products per base pair range
FC27 300–330 95 (51.9) 114 (85.1)
350–380 58 (31.4) 17 (12.7)
400–430 15 (8.1) 2 (1.5)
450–600 16 (8.6) 1 (0.7)
Total FC27 PCR 
products
184 134
HE average HE 
(0.44)
0.62 0.26
3D7 200–300 166 (55.7) 120 (83.3)
320–400 132 (44.3) 22 (16.7)
Total 3D7 PCR 
products
298 144
HE average HE 
(0.39)
0.49 0.28
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scale-up of LLINs has been done [29–32], this study pro-
vides further evidence of a shift towards higher malaria 
risk in older age groups. Results from this study may be 
confounded by the age-distribution differences between 
the two sites, with the higher malaria-endemic Ruhuha 
sector having a higher proportion of sick children aged 
<5 years. A higher risk of P. falciparum infection among 
younger age groups has been reported from elsewhere, 
particularly for severe malaria [33]. The apparent higher 
risk of malaria among younger age groups at the higher 
endemic Ruhuha site was probably due to a lower 
clinical protective immunity among the younger age 
group (<5  years) relative to older age groups (6–15 and 
>15  years) who may have a higher degree of partially 
Fig. 2 Distribution of msp-2 3D7 alleles across Ruhuha and Mubuga study sites in Rwanda
Fig. 3 Distribution of msp-2 FC27 alleles between Ruhuha and Mubuga study sites, Rwanda
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protective immunity already in high transmission set-
tings. In contrast, where malaria control activities, par-
ticularly LLIN usage, were scaled up, malaria risk has 
been observed to shift to older age groups for reasons 
including delays in acquiring immunity and less bed net 
use among the older age groups of 6–15 years, compared 
to children <5  years. A spatial and temporal analysis of 
changing transmission intensities may provide clarity on 
allelic frequency epidemiology as determinants of set-
ting-specific malaria risk.
Among patients enrolled at Ruhuha, a significantly 
higher proportion were females in contrast to those 
recruited at Mubuga where both sexes were propor-
tionally represented. The association between malaria 
risk and sex remains equivocal. In contrast to this 
study’s findings, at the Ruhuha site, a number of previ-
ous studies, including two conducted at the Ruhuha 
site, reported a bias towards higher malaria risk among 
males [31, 32, 34, 35]. The observed higher proportion of 
females at Ruhuha in this study may be a chance occur-
rence due to the non-randomized study design used. 
In addition, females, as seen in Rwanda, tend to have 
better health-seeking behaviour, including more fre-
quent visits to health facilities and are more likely to be 
recruited in health system-based studies than their male 
counterparts. This is the most probable reason for find-
ings reported here, particularly given that it has been 
previously established that males had a higher malaria 
risk in Ruhuha compared to females [31, 34].
In this study, the proportion of patients with a reported 
fever experiences and by a fever ≥37.5 °C differed across 
the two sites. Whilst a higher proportion of Ruhuha-
recruited patients self-reported a history of fever in the 
last  24  h compared to those from Mubuga  and, in con-
trast, a lower proportion of the same patients from 
Ruhuha were confirmed with a measured fever (tympanic 
temperature ≥37.5  °C) compared to Mubuga patients. 
Fever is a common malaria-associated symptom and a 
major  reason for seeking care among suspected malaria 
in endemic settings. At the higher malaria-endemic 
Ruhuha site, it is plausible that residents are more likely 
to associate fever with malaria and hence the higher 
proportion of reported fevers. On the other hand, at the 
lower malaria-endemic Mubuga site, with presumably 
a lower proportion of individuals with partially protec-
tive levels of immunity, patients are more likely to have 
symptomatic malaria infections presenting with fever 
than those at Ruhuha. However, the higher proportion 
of children <5 years old in Ruhuha may have confounded 
the observed higher proportion of reported fevers in 
Ruhuha compared to Mubuga with malaria being asso-
ciated with fever or recent history of fever in infants. In 
contrast, the higher malaria endemicity in Ruhuha may 
plausibly be associated with higher levels of protective 
Table 3 Bivariate analysis for covariate determinants of multiplicity of infection (MOI)
MOI multiplicity of infection; χ2 chi square test; SD standard deviation







Study site All 388 (100 %) 2.13 1.29 1.72 (± 1.02) <0.0001
Study participants  
age group
≤5 years 74 (19.1) 1.92 1.32 1.74 (± 1.05)
6–15 years 188 (48.4) 2.34 1.37 1.86 (± 1.07)
≥16 years 126 (32.5) 1.96 1.21 1.49 (± 0.89) 0.008
Sex Male 173 (44.6) 2.14 1.27 1.66 (± 0.97)
Female 215 (55.4) 2.13 1.32 1.76 (± 1.06) 0.321
Measured fever ≥37.5 °C Yes 188 (48.4) 2.12 1.29 1.79 (± 1.10)
No 200 (51.6) 2.15 1.30 1.63 (± 0.92) 0.119
Reported fever Yes 354 (91.2) 2.14 1.29 1.75 (± 1.05)
No 34 (8.8) 2.00 1.32 1.38 (± 0.65) 0.046
Parasite density  
(parasites/μL)
<1000 176 (45.4) 1.91 1.28 1.51 (± 0.82)
1000-9999 132 (34.0) 2.39 1.31 1.79 (± 1.10)
≥10,000 80 (20.6) 2.12 1.33 2.06 (± 1.18) 0.0002
Number of Plasmodium  
species
P. falciparum only 215 (55.4) 2.33 1.11 1.73 (± 1.03)
P. falciparum and P. ovale) 173 (44.6) 2.13 1.30 1.42 (± 0.67) 0.303
Presence of gametocyte Yes 10 (2.8) 1.50 1.38 1.30 (± 0.56)
No 378 (97.2) 2.14 1.29 1.72 (± 1.03) 0.322
History of sleeping under a  
bed net the night before 
survey
Yes 279 (71.9) 2.21 1.28 1.71 (± 1.09)
No 109 (28.1) 1.99 1.35 1.73 (± 0.84) 0.834
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immunity leading to a lower proportion of malaria com-
pared to persons from the lower-endemic Mubuga site, 
as previously reported from the Ruhuha site [31, 34]. 
Characterizing the association between fever experiences 
and malaria risk is complicated by other determinants 
of measured fevers, including population access to and 
use of antipyretic medications prior to visiting a health 
facility.
In this study, mean MOI was significantly higher at the 
higher malaria-endemic Ruhuha site compared to the 
lower malaria-endemic Mubuga site. While many stud-
ies have reported comparable findings of higher MOI in 
higher endemic settings and correspondingly lower MOI 
in low endemic settings [17, 20, 36, 37], a study in Ghana 
did not find any association between MOI and transmis-
sion intensity [38]. A plausible reason for higher MOI 
in higher endemic settings may be the greater diversity 
and the more frequent meiotic recombination in higher 
malaria transmission settings. In this study, MOI was 
noted to significantly decrease with increasing age. Previ-
ous studies on associations between MOI and age groups 
have shown mixed findings, with some reporting no asso-
ciation [36, 39, 40], while others have reported compara-
ble findings of lower MOI with increasing age have been 
demonstrated in Nigeria, Ghana and Senegal as seen 
in this study [11, 38, 41]. In a Tanzanian study among 
children, MOI peaked among those aged 3–7 years sug-
gesting that younger age groups (<10 years) may be con-
tributing significantly to driving parasite diversity [42]. 
A possible reason for the conflicting findings to those in 
this study may include differences in study age groups 
and study site malaria intensities. It is plausible that mul-
tiple strains are needed to develop immunity in younger 
children and hence the higher diversity in younger chil-
dren. Contrastingly, pre-existing immunity in older age 
groups may be selectively clearing out some strain types 
and hence the noted inverse association between MOI 
and age.
In this study, MOI was positively correlated with para-
site density. This finding accords with previous studies 
where higher MOI among individuals with higher parasite 
densities has been demonstrated [11, 43]. In contrast, no 
association between MOI and level of parasitaemia was 
reported elsewhere [36]. Because parasite densities are 
influenced by multiple determinants including age, levels 
of exposure to malaria infections and area-specific trans-
mission levels, these latter factors may partially—either 
individually or collectively—account for the lack of MOI 
and parasitaemia level associations observed elsewhere.
About 55 % of the P. falciparum msp-2 confirmed iso-
lates carried monoclonal (single allele) infection. By study 
site, a higher proportion of monoclonal infections were 
seen at Mubuga (73.1 %) compared to Ruhuha (38.0 %). 
These data are similar to other studies where higher 
proportions of >50 % and up to 100 % polyclonal infec-
tions have been seen in meso-endemic and holo-endemic 
settings [35, 44, 45]. Similarly, based on msp-1 genetic 
diversity marker, higher proportions of polyclonal infec-
tion have been seen in high endemicity settings, sug-
gesting that malaria parasite polyclonality may be a 
useful proxy measure of level of endemicity [46]. Overall, 
genetic diversity was higher at the more malaria-endemic 
Ruhuha site than at Mubuga whilst 3D7 allelic families 
were more frequent than the FC27 families. At Ruhuha, 
3D7 PCR products were 1.6-fold more than FC27 PCR 
products. Based on msp-1, similar observations of higher 
diversity at a holo-endemic site in Tanzania compared 
to hypo-endemic south-western Brazilian Amazon and 
meso-endemic southern Vietnam has been reported, 
with 3D7 reported as the most frequently circulating 
allele in this study [47].
The majority of msp-2 FC27 alleles belonged to the 
300–330-bp allele family while the most prevalent msp-
2 3D7 allele belonged to the 200–300-bp allele family. 
Between the two sites, while the 300–330-bp allele was 
more frequent at Mubuga, the larger size (350–380, 
400–450, 480–600) allelic families were more common 
at Ruhuha. In contrast to the FC27 gene, the 200–330-
bp allele was the most frequent circulating allele at both 
Ruhuha and Mubuga. Of interest, findings from Mubuga 
of lower allelic diversity and lower frequency of circulat-
ing alleles point to a high likelihood of re-infection with 
the same allele. Differentiating between recrudescence 
and re-infection using msp-2 in a low-endemic setting 
such as Mubuga may be limited by the msp-2 low dis-
criminatory power.
A number of factors, including an adequate sample size, 
use of validated genetic marker for diversity and allelic 
frequency, use of an automated gel reader to determine 
allelic family base pair sizes and a comparative analysis 
for the two study groups drawn from settings of different 
malaria transmission intensities, are major strengths of 
this study. However, there were some limitations. Firstly, 
there was a lack of earlier data on transmission inten-
sity at either study sites to delineate local malaria ende-
micities. Secondly, being a cross-sectional survey design, 
study findings can only provide a baseline comparator 
for current diversity and disease clinical profiles but is 
unable to determine the value of diversity on other dis-
ease outcomes other than parasite density as well as time 
and impact of used intervention related effects. Thirdly, 
the study was done at two sites whilst in Rwanda, malaria 
risk is categorized into four malaria ecologic zones. 
Therefore, study findings may have limited generalizabil-
ity, restricted to settings of comparable transmission and 
malaria control tool implementation levels. Fourthly, due 
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to cost restrictions, we used a valid but lower discrimi-
natory power assay (agarose gel electrophoresis) com-
pared to other assays (e.g. capillary electrophoresis) and 
thus findings may be of a lower accuracy. Lastly, although 
msp-2 is a validated molecular marker of diversity, use 
of one marker may miss variations at other polymorphic 
loci and underestimate the real magnitude of diversity.
Conclusion
This study demonstrated a differential distribution in 
demographics, measured temperature, P. falciparum 
parasite density and genetic diversity as well as allelic dis-
tribution between individuals from two sites of variable 
malaria transmission intensities. HE and mean MOI were 
higher among isolates collected from the higher malaria 
Ruhuha site. Locally, characterizing malaria disease 
severity, based on clinical features and parasitaemia lev-
els, across populations from settings of differing malaria 
transmission intensities is important in profiling malaria 
risk maps and in decision-making on which control tools 
may have optimal impact. The difference in diversity may 
have differential effects on multiple parameters includ-
ing drug-resistant profiles, immunological responses to 
anti-malarial drug and effectiveness of vaccines tested in 
Rwanda in the future.
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